138 related articles for article (PubMed ID: 36386793)
1. Immunotherapy response and microenvironment provide biomarkers of immunotherapy options for patients with lung adenocarcinoma.
Zhan X; Feng S; Zhou X; Liao W; Zhao B; Yang Q; Tan Q; Shen J
Front Genet; 2022; 13():1047435. PubMed ID: 36386793
[No Abstract] [Full Text] [Related]
2. Research into the characteristic molecules significantly affecting liver cancer immunotherapy.
Chen J; Jin H; Zhou H; Hei X; Liu K
Front Immunol; 2023; 14():1029427. PubMed ID: 36860864
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of novel biomarkers affecting bladder cancer immunotherapy
Wang J; He X; Bai Y; Du G; Cai M
Front Immunol; 2022; 13():1051063. PubMed ID: 36439109
[TBL] [Abstract][Full Text] [Related]
4. Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response.
Chen J; Chen S; Dai X; Ma L; Chen Y; Bian W; Sun Y
Front Immunol; 2022; 13():1007326. PubMed ID: 36189254
[TBL] [Abstract][Full Text] [Related]
5. Identification of the alpha linolenic acid metabolism-related signature associated with prognosis and the immune microenvironment in nasopharyngeal carcinoma.
Fang Z; Huang H; Wang L; Lin Z
Front Endocrinol (Lausanne); 2022; 13():968984. PubMed ID: 35992141
[TBL] [Abstract][Full Text] [Related]
6. Exploration of the Immune-Related Long Noncoding RNA Prognostic Signature and Inflammatory Microenvironment for Cervical Cancer.
Yao H; Jiang X; Fu H; Yang Y; Jin Q; Zhang W; Cao W; Gao W; Wang S; Zhu Y; Ying J; Tian L; Chen G; Tong Z; Qi J; Zhou S
Front Pharmacol; 2022; 13():870221. PubMed ID: 35662687
[No Abstract] [Full Text] [Related]
7. Comprehensive Explorations of CCL28 in Lung Adenocarcinoma Immunotherapy and Experimental Validation.
Su X; Wang G; Zheng S; Ge C; Kong F; Wang C
J Inflamm Res; 2023; 16():1325-1342. PubMed ID: 37006812
[TBL] [Abstract][Full Text] [Related]
8. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.
Liu J; Shen H; Gu W; Zheng H; Wang Y; Ma G; Du J
Front Immunol; 2022; 13():960738. PubMed ID: 36032135
[TBL] [Abstract][Full Text] [Related]
9. A signature of tumor immune microenvironment genes associated with the prognosis of non‑small cell lung cancer.
Li J; Li X; Zhang C; Zhang C; Wang H
Oncol Rep; 2020 Mar; 43(3):795-806. PubMed ID: 32020214
[TBL] [Abstract][Full Text] [Related]
10. A Metabolism-Related Gene Prognostic Index for Prediction of Response to Immunotherapy in Lung Adenocarcinoma.
Tang B; Hu L; Jiang T; Li Y; Xu H; Zhou H; Lan M; Xu K; Yin J; Su C; Zhou C; Xu C
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293001
[TBL] [Abstract][Full Text] [Related]
11. Classification of stomach adenocarcinoma based on fatty acid metabolism-related genes frofiling.
Liu C; Tao Y; Lin H; Lou X; Wu S; Chen L
Front Mol Biosci; 2022; 9():962435. PubMed ID: 36090054
[No Abstract] [Full Text] [Related]
12. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.
Wu J; Li L; Zhang H; Zhao Y; Zhang H; Wu S; Xu B
Oncogene; 2021 Jul; 40(26):4413-4424. PubMed ID: 34108619
[TBL] [Abstract][Full Text] [Related]
13. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
14. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research.
Wu L; Zhong Y; Yu X; Wu D; Xu P; Lv L; Ruan X; Liu Q; Feng Y; Liu J; Li X
Anticancer Drugs; 2022 Oct; 33(9):943-959. PubMed ID: 35946526
[TBL] [Abstract][Full Text] [Related]
15. Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma.
Qi X; Qi C; Qin B; Kang X; Hu Y; Han W
Front Oncol; 2020; 10():541330. PubMed ID: 33072571
[No Abstract] [Full Text] [Related]
16. Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients.
Xiao Z; Nie K; Han T; Cheng L; Zhang Z; Peng W; Shi D
J Immunol Res; 2021; 2021():6439975. PubMed ID: 34541005
[TBL] [Abstract][Full Text] [Related]
17. An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma.
Chen H; Lin R; Lin W; Chen Q; Ye D; Li J; Feng J; Cheng W; Zhang M; Qi Y
Sci Rep; 2022 May; 12(1):8230. PubMed ID: 35581376
[TBL] [Abstract][Full Text] [Related]
18. [The Expression of RTN1 in Lung Adenocarcinoma and
Its Effect on Immune Microenvironment].
Zhu S; Zu L; Xu S
Zhongguo Fei Ai Za Zhi; 2022 Jun; 25(6):385-395. PubMed ID: 35747917
[TBL] [Abstract][Full Text] [Related]
19. Research into the biological differences and targets in lung cancer patients with diverse immunotherapy responses.
Zhang X; Wu X; Huang H; Du K; Nie Y; Su P; Li Y
Front Immunol; 2022; 13():1014333. PubMed ID: 36189290
[TBL] [Abstract][Full Text] [Related]
20. An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer.
Zhang F; Feng D; Wang X; Gu Y; Shen Z; Yang Y; Wang J; Zhong Q; Li D; Hu H; Han P
Front Mol Biosci; 2021; 8():780329. PubMed ID: 35004850
[No Abstract] [Full Text] [Related]
[Next] [New Search]
